Nicolaus Andratschke Begins New Chapter as Head of Radiation Oncology at HOCH Health Ostschweiz
@NAndratschke
oncodaily.com/career/nicolau…
Can intentional hotspots improve SBRT outcomes in early-stage NSCLC?
A new retrospective study of 149 lesions found 0 local recurrences with maximum PTV doses ≥120%, vs 8.4% 3-year local recurrence with lower doses.
Promising, but prospective validation is needed.
@Advances_ASTRO
oncodaily.com/oncolibrary/ra…
Radiation Medicine Beyond Cancer Care - Dr. Ronald Chen
@RonaldChenMD
oncodaily.com/science/ronald…
From Eight Weeks to Five Days: New Guidelines for Prostate Cancer Radiotherapy – American Society for Radiation Oncology (ASTRO)
@ASTRO_org
oncodaily.com/new-paper-aler…
Galway University Hospital Brings Radiotherapy Awareness Beyond the Treatment Room – World Radiotherapy Awareness Day
@WorldRTDay
oncodaily.com/community/wrad…
Proton Therapy and Brain Necrosis in Nasopharyngeal Cancer - Edward Christopher "Chris" Dee
@EChrisDee
oncodaily.com/science/edward…
Study Reports High Response Rates to Metastasis-Directed Radiation Therapy in SMARCB1-Deficient RMC - Pavlos Msaouel
@PavlosMsaouel
oncodaily.com/science/pavlos…
Building a Pan-African Radiotherapy Movement – World Radiotherapy Awareness Day
@WorldRTDay
oncodaily.com/community/wrad…
What's new in prostate cancer radiotherapy in 2026?
Our latest OncoDaily RT roundup covers 6 publications on hypofractionation, proton therapy, MRI-guided re-irradiation, long-term toxicity, and patient-reported outcomes.
@RO_GreenJournal
oncodaily.com/oncolibrary/ra…
Gustavo Viani Examines Five Clinical Trials and Their Implications for Individualized Cancer Treatment at ESMO 2026
@gusviani
oncodaily.com/science/gustav…
GORTEC IDEAL at #ESMO2026:
Induction EGFR-ADC becotatug vedotin ± pucotenlimab before CRT in locally advanced HNSCC:
No grade 4 AEs in the first 20 patients.
Grade 3 AEs in 8/20.
Preliminary ORR: 71% (15 evaluable).
Early phase II data; efficacy remains immature.
@myESMO
oncodaily.com/oncolibrary/ra…
At #ESMO2026, a phase II trial of neoadjuvant nivolumab + docetaxel/cisplatin in high-grade salivary gland cancer reported:
MPR: 60.9%
pCR: 32.6%
2-year DFS: 76%
Promising results in 46 operated patients; randomized validation is needed.
@myESMO
oncodaily.com/oncolibrary/ra…
Five Radiation Oncology Studies From ESMO 2026 - Felipe Couñago
@fcounago
oncodaily.com/science/felipe…
UNION phase III at #ESMO2026:
Short-course RT + camrelizumab + CAPOX improved 3-year EFS in locally advanced rectal cancer.
91.3% vs 77.4% (HR 0.33; P=0.0029).
Grade ≥3 toxicity: 51.3% vs 48.2%.
Results presented by Zhen Yu Lin.
@myESMO
oncodaily.com/oncolibrary/ra…
DASL-HiCaP at #ESMO2026:
Adding darolutamide to ADT + RT improved 4-year metastasis-free survival in very high-risk prostate cancer.
MFS: 95% vs 88% (HR 0.42; P=0.0001).
PSA-PFS: 91% vs 83%.
OS benefit not yet established.
oncodaily.com/oncolibrary/ra…
@myESMO
Steven Lin Explores Precision Radiotherapy for Organ Preservation and Cancer Control - Toufic Kachaamy
@KachaamyMD
oncodaily.com/science/toufic…
NRG-GY020 at #ESMO2026:
Adding pembrolizumab to adjuvant RT did not improve 3-year RFS in early-stage high-intermediate-risk dMMR endometrial cancer.
RFS: 70% vs 73% (P=0.68).
3-year OS: 96% in both arms.
Grade 3–4 toxicity: 43% vs 15%.
@myESMO
oncodaily.com/oncolibrary/ra…
iNATURE at #ESMO2026:
Personalized neoantigen vaccine + precision RT improved median PFS to 10.3 vs 3.1 months with placebo + RT (HR 0.29) in 35 patients with advanced solid tumors.
No grade ≥3 vaccine-related AEs.
Promising phase II findings.
@myESMO
oncodaily.com/opinion/inatur…
GITG MASTERPLAN at #ESMO2026:
Adding SBRT to chemotherapy in pancreatic cancer reduced 12-month locoregional recurrence (20.2% vs 52.0%).
Median PFS: 11.9 vs 6.3 months.
Median OS: 22 vs 14 months.
Promising randomized results presented by Andrew Oar.
@myESMO
oncodaily.com/oncolibrary/ra…
